A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-105 in Healthy Subjects
Latest Information Update: 06 Aug 2024
At a glance
- Drugs TAK-105 (Primary)
- Indications Nausea and vomiting
- Focus Adverse reactions
- Sponsors Takeda
- 19 Jun 2023 Status changed from active, no longer recruiting to completed.
- 12 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2023 Planned number of patients changed from 216 to 272.